Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 9/20 | 0.50 |
| ▸ | HRH1 | P35367 | 5/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879203 | 0.87 | TSHR (0.53) | HDAC4HDAC7HDAC5HTR2AHTR2C | |
| SCHEMBL6045078 | 0.86 | ANPEP (0.53) | HDAC4HDAC7HDAC5HTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL11492466 | 0.85 | TSHR (0.56) | HDAC4HDAC7HDAC5HTR2AHTR2C | |
| SCHEMBL71512 | 0.83 | HDAC4 (0.63) | HDAC4HDAC7HDAC5HTR2AHRH1 | |
| SCHEMBL3360436 | 0.81 | HDAC4 (0.49) | HDAC4HDAC7HDAC5HTR2AHRH1 | |
| SCHEMBL10355854 | 0.81 | EDNRA (0.50) | HDAC4HDAC7HDAC5TSHRNPSR1 | |
| SCHEMBL11527593 | 0.81 | EDNRA (0.50) | HDAC4HDAC7HDAC5TSHRNPSR1 | |
| SCHEMBL15075053 | 0.81 | ALDH1A1 (0.62) | HDAC4HDAC7HDAC5HTR2AHRH1 | |
| SCHEMBL5756266 | 0.81 | HDAC4 (0.61) | HDAC4HDAC7HDAC5HTR2AHRH1 | |
| SCHEMBL13005577 | 0.81 | HDAC4 (0.61) | HDAC4HDAC7HDAC5HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214600-A1 | Quaternized Quinuclidine Esters | ALMIRALL PRODESFARMA, SA (ES) | 2008-09-04 | — | — | US | claimed |
| EP-1725552-B1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | claimed |
| EP-1303499-B1 | TETRAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-07-12 | — | — | EP | claimed |
| CN-1214017-C | Tetrazole derivatives | HOFFMANN LA ROCHE (CH) | 2005-08-10 | — | — | CN | claimed |
| CN-1441791-A | Tetrazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-09-10 | — | — | CN | claimed |
| EP-1303499-A1 | TETRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | claimed |
| US-6399641-B1 | FOR THERAPY AND PROPHYLAXIS OF PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND RESTRICTED BRAIN FUNCTION CAUSED BY BYPASS OPERATIONS OR TRANSPLANTS, POOR BLOOD SUPPLY TO THE BRAIN, SPINAL CORD INJURIES ETC. | HOFFMANN-LA ROCHE INC. | 2002-06-04 | — | — | US | claimed |
| US-20020022648-A1 | Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists | HOFFMANN-LA ROCHE INC. | 2002-02-21 | — | — | US | claimed |
| WO-2002006254-A1 | TETRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | claimed |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | disclosed |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2018-07-31 | — | — | US | disclosed |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2017-11-09 | — | — | US | disclosed |
| US-9687478-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2017-06-27 | — | — | US | disclosed |
| EP-1125922-A1 | PYRROLIDINE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF | Welfide Corporation (JP) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001004118-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS | ALMIRALL PRODESFARMA S.A. (ES) | 2001-01-18 | — | — | WO | disclosed |
| WO-1997006178-A1 | PYRIMIDINE NUCLEOSIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-02-20 | — | — | WO | disclosed |
| US-5101059-A | Xanthene compounds | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| WO-1991008190-A1 | AMINO ACID PROTECTING GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
| US-4152356-A | SELECTIVE CARBONYLATION OF 9,10-DIHYDROANTHRACENE TO FORM 9-FORMYL-9,10-DIHYDROANTHRACENE | EXXON RESEARCH & ENGINEERING CO. (US) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214600-A1 | Quaternized Quinuclidine Esters | NQO2, QPCT, QARS1 | HDAC4 1486/4885HDAC7 1742/4885HDAC5 953/4885 |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | HDAC4 2639/4885HDAC7 2989/4885HDAC5 2242/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | HDAC4 3130/4885HDAC7 3120/4885HDAC5 2588/4885 |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | HDAC4 2431/4885HDAC7 2773/4885HDAC5 1961/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | HDAC4 3333/4885HDAC7 3127/4885HDAC5 2587/4885 |
| US-20020022648-A1 | Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists | GRM1, GRM3, GRM2 | HDAC4 929/4885HDAC7 541/4885HDAC5 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.